Replies to post #243023 on Biotech Values

[DewDiligence]

VTRS acquires OYST for $11.00/sh cash—a 32% premium to Friday’s close:

https://www.prnewswire.com/news-releases/viatris-announces-two-acquisitions-to-create-what-it-expects-to-be-a-leading-ophthalmology-franchise-plans-to-provide-strategic-update-on-its-february-2022-investor-event-301670090.html

The deal includes a non-tradeable CVR worth as much as $2/sh. The nominal deal value (excluding the CVR) is about $300M.